1. Incomplete remyelination via therapeutically enhanced oligodendrogenesis is sufficient to recover visual cortical function.
- Author
-
Della-Flora Nunes G, Osso LA, Haynes JA, Conant L, Thornton MA, Stockton ME, Brassell KA, Morris A, Mancha Corchado YI, Gaynes JA, Chavez AR, Woerner MB, MacKenna DA, Alavi A, Danks A, Poleg-Polsky A, Gandhi R, Vivian JA, Denman DJ, and Hughes EG
- Subjects
- Animals, Mice, Visual Cortex drug effects, Visual Cortex physiology, Recovery of Function, Clemastine pharmacology, Clemastine therapeutic use, Male, Female, Visual Pathways drug effects, Disease Models, Animal, Oligodendroglia drug effects, Remyelination drug effects, Remyelination physiology, Demyelinating Diseases physiopathology, Demyelinating Diseases pathology, Myelin Sheath metabolism, Cuprizone toxicity, Mice, Inbred C57BL
- Abstract
Myelin loss induces neural dysfunction and contributes to the pathophysiology of neurodegenerative diseases, injury conditions, and aging. Because remyelination is often incomplete, better understanding endogenous remyelination and developing remyelination therapies that restore neural function are clinical imperatives. Here, we use in vivo two-photon microscopy and electrophysiology to study the dynamics of endogenous and therapeutic-induced cortical remyelination and functional recovery after cuprizone-mediated demyelination in mice. We focus on the visual pathway, which is uniquely positioned to provide insights into structure-function relationships during de/remyelination. We show endogenous remyelination is driven by recent oligodendrocyte loss and is highly efficacious following mild demyelination, but fails to restore the oligodendrocyte population when high rates of oligodendrocyte loss occur quickly. Testing a thyromimetic (LL-341070) compared to clemastine, we find it better enhances oligodendrocyte gain and hastens recovery of neuronal function. The therapeutic benefit of the thyromimetic is temporally restricted, and it acts exclusively following moderate to severe demyelination, eliminating the endogenous remyelination deficit. However, we find regeneration of oligodendrocytes and myelin to healthy levels is not necessary for recovery of visual neuronal function. These findings advance our understanding of remyelination and its impact on functional recovery to inform future therapeutic strategies., Competing Interests: Competing interests: M.B.W., D.A.M., A.A., A.D., J.A.V., and R.G. were employees of Autobahn Therapeutics and hold equity interests in the company. J.A.V. remains an employee of Autobahn Therapeutics. Autobahn Therapeutics developed LL-341070 and provided LL-341070 for experiments. In vitro data and rat gene expression data (Supplementary Fig. 6) were provided by Autobahn Therapeutics. This project was funded in part by a Sponsored Research Agreement between Autobahn Therapeutics and E.G.H. and D.J.D.; academic freedom was maintained in designing and analyzing experiments and in writing the manuscript. All other authors have no other current or past financial involvements with Autobahn Therapeutics, or other competing interests to declare., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF